Avidity Biosciences, Inc. (RNA)

25.80 +1.67 (+6.92%) At close: 04:00PM EDT

Avidity Biosciences, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
United States
858 401 7900
https://www.aviditybiosciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 253

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Sarah Boyce	President, CEO & Director	998.88k	1.16M	1972
Mr. Michael F. MacLean	Chief Financial & Chief Business Officer	674.74k	N/A	1966
Ms. Teresa McCarthy	Chief Human Resources Officer	628.79k	N/A	1964

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Corporate governance

Avidity Biosciences, Inc.’s ISS governance QualityScore as of 29 April 2024 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.